Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis in Retinopathy of Prematurity
NCT02134457Phase 2Completed
- Sponsor
- University Hospital Freiburg
- Start
- Aug 2014
- Primary completion
- Jan 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ranibizumab in retinopathy of prematurity (ROP), sponsored by University Hospital Freiburg. Primary endpoint: Efficacy of treatment at 24 weeks. Started Aug 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT02134457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134457.